Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 536

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Open access
Bonvalot, Sylvie, Rutkowski, Piotr L, Thariat, Juliette, Carrère, Sébastien, Ducassou, Anne, Sunyach, Marie-Pierre, Agoston, Peter, Hong, Angela, Mervoyer, Augustin, Rastrelli, Marco, Moreno, Victor, Li, Rubi K, Tiangco, Béatrice, Herraez, Antonio Casado, Gronchi, Alessandro, Mangel, László, Sy-Ortin, Teresa, Hohenberger, Peter, de Baère, Thierry, Le Cesne, Axel, Helfre, Sylvie, Saada-Bouzid, Esma, Borkowska, Aneta, Anghel, Rodica, Co, Ann, Gebhart, Michael, Kantor, Guy, Montero, Angel, Loong, Herbert H, Vergés, Ramona, Lapeire, Lore, Dema, Sorin, Kacso, Gabriel, Austen, Lyn, Moureau-Zabotto, Laurence, Servois, Vincent, Wardelmann, Eva, Terrier, Philippe, Lazar, Alexander J, Bovée, Judith V M G, Le Péchoux, Cécile, Papai, Zsusanna·2019·The Lancet Oncology

Abstract

BACKGROUND Pathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving radiotherapy. This phase 2-3 trial evaluated the safety and efficacy of the hafnium oxide (HfO2) nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma. METHODS Act.In.Sarc is a phase 2-3 randomised, multicentre, international trial. Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included. Patients had to have a WHO performance status of 0-2 and a life expectancy of at least 6 months. Patients were randomly assigned (1:1) by an interactive web response system to receive either NBTXR3 (volume corresponding to 10% of baseline tumour volume at a fixed concentration of 53·3 g/L) as a single intratumoural administration before preoperative external-beam radiotherapy (50 Gy in 25 fractions) or radiotherapy alone, followed by surgery. Randomisation was stratified by histological subtype (myxoid liposarcoma vs others). This was an open-label study. The primary endpoint was the proportion of patients with a pathological complete response, assessed by a central pathology review board following European Organisation for Research and Treatment of Cancer guidelines in the intention-to-treat population full analysis set. Safety analyses were done in all patients who received at least one puncture and injection of NBTXR3 or at least one dose of radiotherapy. This study is registered with ClinicalTrials.gov, number NCT02379845, and is ongoing for long-term follow-up, but recruitment is complete. FINDINGS Between March 3, 2015, and Nov 21, 2017, 180 eligible patients were enrolled and randomly assigned and 179 started treatment: 89 in the NBTXR3 plus radiotherapy group and 90 in the radiotherapy alone group. Two patients in the NBTXR3 group and one patient in the radiotherapy group were excluded from the efficacy analysis because they were subsequently discovered to be ineligible; thus, a total of 176 patients were analysed for the primary endpoint in the intention-to-treat full analysis set (87 in the NBTXR3 group and 89 in the radiotherapy alone group). A pathological complete response was noted in 14 (16%) of 87 patients in the NBTXR3 group and seven (8%) of 89 in the radiotherapy alone group (p=0·044). In both treatment groups, the most common grade 3-4 treatment-emergent adverse event was postoperative wound complication (eight [9%] of 89 patients in the NBTXR3 group and eight [9%] of 90 in the radiotherapy alone group). The most common grade 3-4 adverse events related to NBTXR3 administration were injection site pain (four [4%] of 89) and hypotension (four [4%]) and the most common grade 3-4 radiotherapy-related adverse event was radiation skin injury in both groups (five [6%] of 89 in the NBTXR3 group and four [4%] of 90 in the radiotherapy alone group). The most common treatment-emergent grade 3-4 adverse event related to NBTXR3 was hypotension (six [7%] of 89 patients). Serious adverse events were observed in 35 (39%) of 89 patients in the NBTXR3 group and 27 (30%) of 90 patients in the radiotherapy alone group. No treatment-related deaths occurred. INTERPRETATION This trial validates the mode of action of this new class of radioenhancer, which potentially opens a large field of clinical applications in soft-tissue sarcoma and possibly other cancers. FUNDING Nanobiotix SA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30326-2

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 536

Metadata

Authors
Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M.-P., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., Moreno, V., Li, R. K., Tiangco, B., Herraez, A. C., Gronchi, A., Mangel, L., Sy-Ortin, T., Hohenberger, P., de Baère, T., Le Cesne, A., Helfre, S., Saada-Bouzid, E., Borkowska, A., Anghel, R., Co, A., Gebhart, M., Kantor, G., Montero, A., Loong, H. H., Vergés, R., Lapeire, L., Dema, S., Kacso, G., Austen, L., Moureau-Zabotto, L., Servois, V., Wardelmann, E., Terrier, P., Lazar, A. J., Bovée, J. V. M. G., Le Péchoux, C., & Papai, Z.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-08
Volume
20
Issue
8
Pages
1148-1159
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2961319233
Cited by
536
References
33
FWCI
35.58
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30326-2
The paper
Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M.-P., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., Moreno, V., Li, R. K., Tiangco, B., Herraez, A. C., Gronchi, A., Mangel, L., Sy-Ortin, T., Hohenberger, P., de Baère, T., . . . Papai, Z. (2019). NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30326-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.